Oxamyl dipeptide caspase inhibitors developed for the treatment of stroke

Bioorganic and Medicinal Chemistry Letters

Volumn 14, Issue 10, 2004, Pages 2685-2691

  Linton, Steven D ^a   Aja, Teresa ^a   Allegrini, Peter R ^b   Deckwerth, Thomas L ^a   Diaz, Jose Luis ^a   Hengerer, Bastian ^b   Herrmann, Julia ^a   Jahangiri, Kathy G ^a   Kallen, Joerg ^b   Karanewsky, Donald S ^a   Meduna, Steven P ^a   Nalley, Kip ^a   Robinson, Edward D ^a   Roggo, Silvio ^b   Rovelli, Giorgio ^b   Sauter, Andre ^b   Sayers, Robert O ^a   Schmitz, Albert ^b   Smidt, Robert ^a   Ternansky, Robert J ^a   Tomaselli, Kevin J ^a   Ullman, Brett R ^a   Wiessner, Christoph ^b   Wu, Joe C ^a   more..

^a PFIZER INC   (United States)

^b NOVARTIS PHARMA AG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE; CASPASE INHIBITOR; OXAMYL DIPEPTIDE CASPASE; OXAMYL DIPEPTIDE CASPASE INHIBITOR; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DRUG SCREENING; ENZYME INHIBITION; NONHUMAN; RAT; STROKE; STRUCTURE ACTIVITY RELATION;

APOPTOSIS; CARBAMATES; CASPASES; CELL LINE; CEREBROVASCULAR ACCIDENT; DIPEPTIDES; HUMANS; INHIBITORY CONCENTRATION 50; KINETICS; NEURODEGENERATIVE DISEASES; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 11144354772     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2003.12.106     Document Type: Article

References (32)

1. For nomenclature of the caspase family, see: Alnemri E.S., Livingston D.J., Nicholson D.W., Salvesen G., Thornberry N.A., Wong W.W., Yuan J.-Y. Cell. 87:1996;171.
2. Thornberry N.A. Chem. Biol. 5:1998;R97.
3. Black R.A., Kronheim S.R., Sleath P.R. FEBS Lett. 247:1989;386.
4. Ellis R.E., Yuan J., Horvitz H.R. Ann. Rev. Cell Biol. 7:1991;663.
5. Reed J.C., Tomaselli K.J. Curr. Opin. Biotech. 11:2000;586.
6. Talanian R.V., Brady K.D., Cryns V.L. J. Med. Chem. 43:2000;3351.
7. Lee D., Long S.A., Murray J.H., Adams J.L., Nutall M.E., Nadeau D.P., Kikly K., Winkler J.D., Sung C.-M., Ryan M.D., Levy M.A., Keller P.M., DeWolf W.E. J. Med. Chem. 44:2000;2015.
8. Guo Z.-M., Xian M., Zhang W., McGill A., Wang P.G. Bioorg. Med. Chem. 9:2001;99.
9. Shahripour A.B., Plummer M.S., Lunney E.A., Sawyer T.K., Stankovic C.J., Connolly M.K., Rubin J.R., Walker N.P.C., Brady K.D., Allen H.J., Talanian R.V., Wong W.W., Humblet C. Bioorg. Med. Chem. Lett. 11:2001;2779.
10. Shahripour A.B., Plummer M.S., Lunney E.A., Albrecht H.P., Hays S.J., Kostlan C.R., Sawyer T.K., Walker N.P.C., Brady K.D., Allen H.J., Talanian R.V., Wong W.W., Humblet C. Bioorg. Med. Chem. Lett. 10:2002;31.
11. Choong I.C., Lew W., Lee D., Phuongly P., Burdett M.T., Lam J.W., Wiesmann C., Luong T.N., Fahr B., DeLano W.L., McDowell R.S., Allen D.A., Erlanson D.A., Gordon E.M., O'Brien T. J. Med. Chem. 45:2002;5005.
12. Han B.H., Xu D., Choi J., Han Y., Xanthoudakis S., Roy S., Tam J., Vaillancourt J., Colucci J., Siman R., Giroux A., Robertson G.S., Zamboni R., Nicholson D.W., Holtzman D.M. J. Biol. Chem. 277:2002;30128.
13. For a review of the caspase inhibitor patent literature, see: Ashwell S. Exp. Opin. Ther. Patents. 11:2001;1593.
14. Karanewsky, D. S.; Kalish, V. J.; Robinson, E. D.; Ullman, B. R. U.S. Patent 6,242,422 B1, 2001.
15. Linton S.D., Karanewsky D.S., Ternansky R.J., Wu J.C., Pham B., Kodandapani L., Smidt R., Diaz J.L., Fritz L.C., Tomaselli K.J. Bioorg. Med. Chem. Lett. 12:2002;2969.
16. Mittl P.R.E., DiMarco S., Krebs J.F., Bai X., Karanewsky D.S., Priestle J.P., Tomaselli K.J., Grutter M.K. J. Biol. Chem. 272:1997;6539.
17. Linton S.D., Karanewsky D.S., Ternansky R.J., Chen N., Guo X., Jahangiri K.G., Kalish V.J., Meduna S.P., Robinson E.D., Ullman B.R., Wu J.C., Pham B., Kodandapani L., Smidt R., Diaz J.L., Fritz L.C., Krosigk U., Roggo S., Schmitz A., Tomaselli K.J. Bioorg. Med. Chem. Lett. 12:2002;2973.
18. (a) Karanewsky, D. S.; Ternansky, R. J. U.S. Patent 6,197,750, 2001.
19. (b) Karanewsky, D. S.; Ternansky, R. J.; Linton, S. D.; Dinh, T. PCT Patent Application WO 02/057298, 2002.
20. Assay definitions: (a) Monocyte: Primary monocytes isolated from peripheral human blood by Dextran sedimentation and Ficoll. Cells were stimulated overnight with staph A. Inhibition of IL-1β production evaluated with human IL-1β ELISA assay (R&D Systems). See: Bleeker M.W.P., Netea M.G., Kullberg B.J., van der Ven-Jongekrijgg J., van der Meer J.W. Immunology. 91:1997;548.
21. Hamon Y., Luciani M.-F., Becq F., Verrier B., Rubartelli A., Chimini G. Blood. 90:1997;2911.
22. Con A: Rat embryonic cortical neurons exposed to 100 nM concanaval A for 24 h; survival measured by MTS reduction. See: Deckwerth T.L., Adams L.M., Wiessner C., Allegrini P.R., Rudin M., Sauter A., Hengerer B., Sayers R.O., Rovelli G., Aja T., May R., Nalley K., Linton S., Karanewsky D.S., Wu J.C., Roggo S., Schmitz A., Contreras P.C., Tomaselli K.T. Drug Dev. Res. 52:2001;579.
23. -1 anti-fas (CH-11) for 24 h. Viability evaluated with MTT. See: Armstrong R.C., Aja T., Xiang J., Gaur S., Krebs J.F., Hoang K., Bai X., Korsmeyer S.J., Karanewsky D.S., Fritz L.C., Tomaselli K.J. J. Biological. Chem. 271:1996;16850.
24. THP-1: Human monocytic cell line primed with interferon-γ. Cells were stimulated overnight with LPS (lipopolysaccharide). Inhibition of IL-1β production evaluated with human I ELISA assay (R&D Systems). See: Humphreys B.D., Dubyak G.R. J. Immunol. 1996;5627. For more detailed assay conditions, see Ref. 8.
25. Scheme 1 describes the synthetic path using valine; similar chemistry was used for the leucine analogues.
26. Ullman B.R., Aja T., Deckwerth T.L., Diaz J.L., Herrman J., Kalish V.J., Karanewsky D.S., Meduna S.P., Nalley K., Robinson E.D., Roggo S.P., Sayers R.O., Schmitz A., Ternansky R.J., Tomaselli K.J., Wu J.C. Bioorg. Med. Chem. Lett. 13:2003;3623.
27. Krantz A., Copp L.J., Coles P.J., Smith R.A., Heard S.B. Biochemistry. 30:1991;4678.
28. Dolle R.E., Hoyer D., Prasad C.V.C., Schmidt S.J., Helaszek C.T., Miller R.E., Ator M.A. J. Med. Chem. 37:1994;563.
29. March J. Advanced Organic Chemistry: Reactions, Mechanisms, and Structure. 4th ed. 1992;430-431 John Wiley, New York. and references cited therein.
30. Wu J.C., Fritz L.C. Methods. 17:1999;320.
31. Dolle R.E., Singh J., Whipple D.I., Osifo K., Speier G., Graybill T.L., Gregory J.S., Harris A.L., Helaszek C.T., Ator M.A. J. Med. Chem. 38:1995;220.
32. Analogue 78 was administered iv @ 1, 3, and 5 h post-occlusion to male Fischer 344 rats. Vehicle used was 5% Tween 80. Infarct volume was measured at 24 h using T2-weighted MRI. Reduction in infarct size was statistically significant, p<0.05.